Zobrazeno 1 - 10
of 361
pro vyhledávání: '"J. Bloemendal"'
Autor:
J. Bloemendal
Publikováno v:
BMGN: Low Countries Historical Review, Vol 126, Iss 2 (2011)
Externí odkaz:
https://doaj.org/article/0efe5d047f4243eca04b935b31fbf999
Autor:
Karlijn Verkerk, Birgit S. Geurts, Laurien J. Zeverijn, Vincent van der Noort, Henk M.W. Verheul, John B.A.G. Haanen, Astrid A.M. van der Veldt, Ferry A.L.M. Eskens, Maureen J.B. Aarts, Carla M.L. van Herpen, Mathilde Jalving, Jourik A. Gietema, Lot A. Devriese, Mariette Labots, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Egbert F. Smit, Haiko J. Bloemendal
Publikováno v:
The Lancet Regional Health. Europe, Vol 39, Iss , Pp 100875- (2024)
Summary: Background: The DRUG Access Protocol provides patients with cancer access to registered anti-cancer drugs that are awaiting reimbursement in the Netherlands and simultaneously collects prospective real-world data (RWD). Here, we present RWD
Externí odkaz:
https://doaj.org/article/fc99db69ccab44d8b32b3ad075d188c3
Autor:
Hilin Yildirim, Christiaan V Widdershoven, Maureen JB Aarts, Axel Bex, Haiko J Bloemendal, Deirdre M Bochove-Overgaauw, Paul Hamberg, Karin H Herbschleb, Tom van der Hulle, Brunolf W Lagerveld, Martijn GH van Oijen, Sjoukje F Oosting, Johannes V van Thienen, Astrid AM van der Veldt, Hans M Westgeest, Evelijn E Zeijdner, Katja KH Aben, Corina van den Hurk, Patricia J Zondervan, Adriaan D Bins
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background Ongoing research in the field of both localized, locally advanced and metastatic renal cell carcinoma has resulted in the availability of multiple treatment options. Hence, many questions are still unanswered and await further res
Externí odkaz:
https://doaj.org/article/7899867013894664a81995245ef9db90
Autor:
Cilla E. J. Vrinzen, Haiko J. Bloemendal, Esra Stuart, Amr Makady, Michel vanAgthoven, Mariska Koster, Matthias A. W. Merkx, Rosella P. M. G. Hermens, Patrick P. T. Jeurissen
Publikováno v:
Cancer Medicine, Vol 12, Iss 5, Pp 6105-6116 (2023)
Abstract Background Cancer rates and expenditures are increasing, resulting in debates on the exact value of this care. Perspectives on what exactly constitutes worthwhile values differ. This study aims to explore all values–elements regarding new
Externí odkaz:
https://doaj.org/article/c98f3e2beaef40ca8faa6f89adb2a9e3
Autor:
Sjoerd O Klaver, André N Vis, Gerard Vreugdenhil, Haiko J Bloemendal, Pieter L van den Berg, Niven Mehra, Mathijs P Hendriks, Tessa van Elst, Sjaak Bloem, Zarina Lalmahomed, Daphne Luijendijk, Jean-Paul A van Basten, Roderick CN van den Bergh, Joyce M van Dodewaard-de Jong, Addy CM van de Luijtgaarden, Luc AJ Roelofs, Eric HJEJ Vrijhof, Bart P Wijsman, Peter FA Mulders
Publikováno v:
BMJ Open, Vol 13, Iss 8 (2023)
Introduction The treatment landscape for de novo metastatic hormone sensitive prostate cancer (mHSPC) is rapidly evolving. With an abundance of available treatment strategies, selecting the optimal strategy for an individual patient is becoming incre
Externí odkaz:
https://doaj.org/article/801ee6f62ee04d6d870bfa0478fe2607
Autor:
Niek A. Peters, Alexander Constantinides, Inge Ubink, Joyce van Kuik, Haiko J. Bloemendal, Joyce M. van Dodewaard, Menno A. Brink, Thijs P. Schwartz, Martijn P.J.K. Lolkema, Miangela M. Lacle, Leon M. Moons, Joost Geesing, Wilhelmina M.U. van Grevenstein, Jeanine M. L. Roodhart, Miriam Koopman, Sjoerd G. Elias, Inne H.M. Borel Rinkes, Onno Kranenburg
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundMesenchymal Consensus Molecular Subtype 4 (CMS4) colon cancer is associated with poor prognosis and therapy resistance. In this proof-of-concept study, we assessed whether a rationally chosen drug could mitigate the distinguishing molecular
Externí odkaz:
https://doaj.org/article/aa2ea800e7be4277afea3b34814f26b9
Autor:
Patrick P.T. Jeurissen, Haiko J. Bloemendal, Matthias A.W. Merkx, Rosella P.M.G. Hermens, Niek Stadhouders, Linn Delfgou, Cilla E.J. Vrinzen
Comorbidities can have major implications for cancer care, as they might impact the timing of cancer diagnosis, compromise optimal care, affect treatment outcomes, and increase healthcare costs. Thus, it is important to comprehensively evaluate cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::040a744cf0c0ddfeea898f7dfa458399
https://doi.org/10.1158/0008-5472.c.6487381.v2
https://doi.org/10.1158/0008-5472.c.6487381.v2
Autor:
Anne J Boonman, Maarten Cuypers, Geraline L Leusink, Jenneken Naaldenberg, Haiko J Bloemendal
Publikováno v:
Lancet Oncology, 23, 4, pp. e174-e183
Lancet Oncology, 23, e174-e183
Lancet Oncology, 23, e174-e183
Item does not contain fulltext Adults with intellectual disabilities face disparities in receipt of cancer-related care, which could contribute to an increase in the rate of cancer-related deaths in this population. Yet, relatively little is known ab
Autor:
Patrick P.T. Jeurissen, Haiko J. Bloemendal, Matthias A.W. Merkx, Rosella P.M.G. Hermens, Niek Stadhouders, Linn Delfgou, Cilla E.J. Vrinzen
Supplementary tables and figure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::671371362c1ae8d1801c0cec08f4b2b4
https://doi.org/10.1158/0008-5472.22361318
https://doi.org/10.1158/0008-5472.22361318
Autor:
Cilla E.J. Vrinzen, Linn Delfgou, Niek Stadhouders, Rosella P.M.G. Hermens, Matthias A.W. Merkx, Haiko J. Bloemendal, Patrick P.T. Jeurissen
Publikováno v:
Cancer Research, 83, 7, pp. 1147-1157
Cancer Research, 83, 1147-1157
Cancer Research, 83, 1147-1157
Comorbidities can have major implications for cancer care, as they might impact the timing of cancer diagnosis, compromise optimal care, affect treatment outcomes, and increase healthcare costs. Thus, it is important to comprehensively evaluate cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e61de98a3cbd9b8ab7cdd0ab3025b8b
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/291761
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/291761